Forbius Completes Phase 1 Oncology Dose-Escalation with AVID200, First-in-Class TGF-beta 1 & 3 Inhibitor: Well Tolerated, Target Inhibition Demonstrated at All Dose Levels, Data Reported at SITC

November 8, 2019 by Website Admin in

Tweet

Share

Pin it

Previous StorySaranas Announces First Commercial Case With Early Bird® Bleed Monitoring System in the U.S. Next StoryTMC Innovation Announces New Model for the TMCx Accelerator